Bayer Ascensia recall marked "class I"
This article was originally published in Clinica
The FDA has slapped a class 1 label - the most serious category - on Bayer Healthcare's recall of its Ascensia Contour blood glucose monitoring system. The company initiated the recall after discovering 16 of the glucose meters, distributed in Canada, had not been adjusted to display the correct measure for Canadian users.
You may also be interested in...
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.